Status:
COMPLETED
Efficacy and Safety Study of Apixaban for the Treatment of Deep Vein Thrombosis or Pulmonary Embolism
Lead Sponsor:
Bristol-Myers Squibb
Collaborating Sponsors:
Pfizer
Conditions:
Venous Thrombosis
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
The purpose of this study is to evaluate the effects of an investigational blood thinner, apixaban, in preventing venous thromboembolic (VTE) recurrence or death in patients with deep vein thrombosis ...
Eligibility Criteria
Inclusion
- Men and women ≥ 18 years of age
- Clinical diagnosis of DVT or PE
Exclusion
- Contraindications for enoxaparin or warfarin
- Active bleeding or high risk for serious bleeding
- Short life expectancy
- Uncontrolled high blood pressure
- Significantly impaired kidney or liver function
Key Trial Info
Start Date :
July 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2013
Estimated Enrollment :
5614 Patients enrolled
Trial Details
Trial ID
NCT00643201
Start Date
July 1 2008
End Date
March 1 2013
Last Update
April 21 2014
Active Locations (381)
Enter a location and click search to find clinical trials sorted by distance.
1
Alabama Clinical Therapeutics, Llc
Birmingham, Alabama, United States, 35235
2
Horizon Research Group, Inc.
Mobile, Alabama, United States, 36608
3
Fort Smith Lung Center
Fort Smith, Arkansas, United States, 72901
4
University Of Arkansas For Medical Sciences
Little Rock, Arkansas, United States, 72205